Revlimid

'Monopoly' allowed Bristol Myers and generics makers to 'steal' from Revlimid purchasers, lawsuit says
'Monopoly' allowed Bristol Myers and generics makers to 'steal' from Revlimid purchasers, lawsuit says
Fierce Pharma
Bristol Myers Squibb
Celgene
Revlimid
patents
generics
Flag link:
Even as Revlimid's star fades, Bristol Myers' core offerings have reached a 'critical mass,' CEO says
Even as Revlimid's star fades, Bristol Myers' core offerings have reached a 'critical mass,' CEO says
Fierce Pharma
Bristol Myers Squibb
generics
Revlimid
Abecma
Breyanzi
Pharma CEOs
Giovanni Caforio
Flag link:
Janssen reports Phase II data for Darzalex-RVd to treat multiple myeloma
Janssen reports Phase II data for Darzalex-RVd to treat multiple myeloma
Clinical Trials Arena
JNJ
Janssen
clinical trials
Darzalex
Revlimid
Velcade
Multiple Myeloma
Flag link:
The patent winter is coming
The patent winter is coming
EP Vantage
patents
biosimilars
patent cliff
Keytruda
Opdivo
Eliquis
Darzalex
Revlimid
Humira
Stelara
AbbVie
Merck
Bristol Myers Squibb
JNJ
Flag link:
Bristol Myers Squibb's Revlimid finally faces competition in the U.S. with Teva's generic launch
Bristol Myers Squibb's Revlimid finally faces competition in the U.S. with Teva's generic launch
Fierce Pharma
Bristol Myers Squibb
Revlimid
Multiple Myeloma
generics
Teva Pharmaceutical
Flag link:
JPM 2022: Bristol Myers plots 3 blockbuster launches to counter Revlimid's patent cliff
JPM 2022: Bristol Myers plots 3 blockbuster launches to counter Revlimid's patent cliff
Fierce Pharma
JPMHC 2022
Bristol Myers Squibb
Revlimid
patent cliffs
Opdivo
Eliquis
Reblozyl
Breyanzi
Flag link:
#JPM22, Day 1: Bristol Myers Squibb's blockbuster losses of exclusivity, Novartis' spending plans and more
#JPM22, Day 1: Bristol Myers Squibb's blockbuster losses of exclusivity, Novartis' spending plans and more
Fierce Pharma
JPMHC 2022
Bristol Myers Squibb
Revlimid
Novartis
Moderna Therapeutics
JNJ
Trikafta
Flag link:
Bristol Myers Squibb, Amgen and Pfizer approach steepest patent cliffs among large drugmakers
Bristol Myers Squibb, Amgen and Pfizer approach steepest patent cliffs among large drugmakers
Fierce Pharma
patents
patent cliffs
Bristol Myers Squibb
Amgen
Pfizer
Revlimid
Eliquis
Enbrel
Otezla
Ibrance
Flag link:
The top 15 blockbuster patent expirations coming this decade
The top 15 blockbuster patent expirations coming this decade
Fierce Pharma
patents
patent cliff
AbbVie
Humira
Merck
Keytruda
Bristol Myers Squibb
Revlimid
Pfizer
Eliquis
Regeneron
Eylea
JNJ
Stelara
Opdivo
GSK
Dolutegravir
Ibrance
Januvia
Eli Lilly
Trulicity
Novo Nordisk
Victoza
Amgen
Prolia
Xgeva
Novartis
Cosentyx
Takeda
Entyvio
Flag link:
Bristol Myers inks another Revlimid patent settlement—this time with Sun Pharma—as copycats near
Bristol Myers inks another Revlimid patent settlement—this time with Sun Pharma—as copycats near
Fierce Pharma
Bristol Myers Squibb
Celgene
Revlimid
generics
Sun Pharma
patents
Flag link:
Bristol Myers Squibb can grow through Revlimid generics, execs insist, pointing to key launches
Bristol Myers Squibb can grow through Revlimid generics, execs insist, pointing to key launches
Fierce Pharma
Bristol-Myers Squibb
generics
Revlimid
Zeposia
Reblozyl
Onureg
Flag link:
Congressional investigation reveals Celgene, Teva plotted to keep drug prices high
Congressional investigation reveals Celgene, Teva plotted to keep drug prices high
RAPS.org
congress
Celgene
Teva Pharmaceutical
Revlimid
Copaxone
drug pricing
Flag link:
Bristol-Myers Squibb Cuts Deal, Delaying Threat to Top-Selling Revlimid
Bristol-Myers Squibb Cuts Deal, Delaying Threat to Top-Selling Revlimid
Motley Fool
Bristol-Myers Squibb
Dr Reddy's
Revlimid
Multiple Myeloma
Flag link:
2 newer multiple myeloma drugs fall short in bid for wider market
2 newer multiple myeloma drugs fall short in bid for wider market
BioPharma Dive
Multiple Myeloma
clinical trials
Bristol-Myers Squibb
Takeda
Ninlaro
Empliciti
Revlimid
Flag link:
Bristol Myers flunks frontline multiple myeloma trial, turning attention to cell therapy
Bristol Myers flunks frontline multiple myeloma trial, turning attention to cell therapy
Endpoints
Bristol-Myers Squibb
Celgene
M&A
clinical trials
Multiple Myeloma
Empliciti
AbbVie
Revlimid
Flag link:
Bristol-Myers Placed A Big Bet On Celgene’s Pipeline. Will It Pay Off For Investors?
Bristol-Myers Placed A Big Bet On Celgene’s Pipeline. Will It Pay Off For Investors?
Motley Fool
Bristol-Myers Squibb
Celgene
M&A
Revlimid
patents
Flag link:
The top drugs facing cuts under Pelosi's pricing plan
The top drugs facing cuts under Pelosi's pricing plan
Biopharma Dive
drug pricing
Nancy Pelosi
regulatory
Revlimid
Keytruda
Opdivo
Januvia
insulin
Medicare
Flag link:
How Big Is Celgene's Latest Good News?
How Big Is Celgene's Latest Good News?
Motley Fool
Celgene
Otezla
Revlimid
Inrebic
Flag link:
FDA Action Alert: Regeneron, Sanofi, Celgene
FDA Action Alert: Regeneron, Sanofi, Celgene
BioSpace
FDA
drug approvals
Acer Therapeutics
Edsivo
Regeneron
Sanofi
Dupixent
Celgene
Revlimid
Alexion
Soliris
Dova Pharmaceuticals
Doptelet
Nabriva Therapeutics
Contepo
Retrophin
Thiola
Flag link:
Meet the Top Ten Drugs of 2024 (Maybe)
Meet the Top Ten Drugs of 2024 (Maybe)
Drug Channels
AbbVie
Humira
Merck
Keytruda
Eliquis
Bristol-Myers Squibb
Imbruvica
Opdivo
Revlimid
Celgene
Flag link:

Pages